TRXADE HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.31 USD | +0.80% |
|
-1.87% | +21.43% |
| Apr. 22 | TRxADE HEALTH, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | Top Midday Gainers | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9.686 | 42.89 | 42.81 | 19.27 | 3.752 | 6.481 |
| Enterprise Value (EV) 1 | 9.66 | 41.01 | 37.52 | 17.4 | 4.202 | 13.43 |
| P/E ratio | 1,160 x | -132 x | -16.1 x | -3.61 x | -0.98 x | -0.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.53 x | 5.77 x | 2.5 x | 1.95 x | 0.33 x | 0.78 x |
| EV / Revenue | 2.52 x | 5.52 x | 2.19 x | 1.76 x | 0.37 x | 1.62 x |
| EV / EBITDA | - | 82,229,017 x | -21,136,247 x | -3,292,138 x | -1,161,681 x | -1,854,308 x |
| EV / FCF | 57.8 x | 317 x | -24.7 x | -34.5 x | -3.91 x | -6.13 x |
| FCF Yield | 1.73% | 0.32% | -4.05% | -2.9% | -25.6% | -16.3% |
| Price to Book | 11.8 x | 10.4 x | 4.93 x | 5.11 x | 4.96 x | 8.67 x |
| Nbr of stocks (in thousands) | 359 | 433 | 540 | 544 | 621 | 1,247 |
| Reference price 2 | 27.00 | 99.00 | 79.35 | 35.40 | 6.039 | 5.196 |
| Announcement Date | 3/22/19 | 3/30/20 | 3/29/21 | 3/28/22 | 3/27/23 | 4/22/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3.832 | 7.436 | 17.12 | 9.889 | 11.45 | 8.272 |
| EBITDA | - | 0.4987 | -1.775 | -5.285 | -3.617 | -7.244 |
| EBIT 1 | -0.0876 | 0.4937 | -1.781 | -5.292 | -3.632 | -7.263 |
| Operating Margin | -2.29% | 6.64% | -10.4% | -53.51% | -31.72% | -87.8% |
| Earnings before Tax (EBT) 1 | 0.009038 | -0.2844 | -2.536 | -5.316 | -3.91 | -13.72 |
| Net income 1 | 0.009038 | -0.2844 | -2.536 | -5.316 | -3.472 | -17.84 |
| Net margin | 0.24% | -3.82% | -14.81% | -53.75% | -30.33% | -215.7% |
| EPS 2 | 0.0233 | -0.7500 | -4.937 | -9.800 | -6.147 | -23.35 |
| Free Cash Flow 1 | 0.1671 | 0.1295 | -1.521 | -0.5046 | -1.074 | -2.193 |
| FCF margin | 4.36% | 1.74% | -8.88% | -5.1% | -9.38% | -26.51% |
| FCF Conversion (EBITDA) | - | 25.96% | - | - | - | - |
| FCF Conversion (Net income) | 1,849.03% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/22/19 | 3/30/20 | 3/29/21 | 3/28/22 | 3/27/23 | 4/22/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.55 | 2.388 | 3.24 | 3.279 | 2.4 | 2.529 | 2.248 | 2.251 |
| EBITDA | -1.177 | -0.843 | -0.8997 | -1.064 | -0.4042 | 2.274 | -0.5864 | - |
| EBIT 1 | -1.296 | -0.781 | -0.9686 | -1.103 | -0.407 | -1.946 | -0.3474 | -0.3456 |
| Operating Margin | -50.83% | -32.71% | -29.89% | -33.64% | -16.96% | -76.93% | -15.46% | -15.35% |
| Earnings before Tax (EBT) 1 | -1.302 | -0.7843 | -0.9658 | -1.112 | -0.5287 | -0.8653 | -0.3257 | -1.975 |
| Net income 1 | -1.302 | -0.7843 | -0.9602 | -1.084 | -0.503 | -0.8653 | -0.678 | -1.975 |
| Net margin | -51.05% | -32.85% | -29.63% | -33.05% | -20.96% | -34.21% | -30.16% | -87.73% |
| EPS 2 | -2.400 | -1.350 | -1.800 | -1.950 | -0.9000 | -1.500 | -1.050 | -43.50 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/25/21 | 3/28/22 | 5/9/22 | 7/25/22 | 11/7/22 | 3/27/23 | 5/15/23 | 8/18/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.45 | 6.95 |
| Net Cash position 1 | 0.03 | 1.87 | 5.29 | 1.87 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.1245 x | -0.9597 x |
| Free Cash Flow 1 | 0.17 | 0.13 | -1.52 | -0.5 | -1.07 | -2.19 |
| ROE (net income / shareholders' equity) | 3.39% | -11.4% | -39.6% | -85.4% | -190% | -3,100% |
| ROA (Net income/ Total Assets) | -3.85% | 7.91% | -14.5% | -42.5% | -47.9% | -55.9% |
| Assets 1 | -0.2348 | -3.594 | 17.51 | 12.5 | 7.248 | 31.92 |
| Book Value Per Share 2 | 2.280 | 9.500 | 16.10 | 6.920 | 1.220 | 0.6000 |
| Cash Flow per Share 2 | 2.350 | 6.590 | 11.00 | 5.740 | 1.810 | 0.1700 |
| Capex 1 | 0.02 | 0.08 | 0.04 | 0.02 | - | - |
| Capex / Sales | 0.39% | 1.11% | 0.22% | 0.23% | - | - |
| Announcement Date | 3/22/19 | 3/30/20 | 3/29/21 | 3/28/22 | 3/27/23 | 4/22/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +21.43% | 8.87M | |
| +18.66% | 414B | |
| +15.27% | 242B | |
| +20.63% | 104B | |
| +17.19% | 83.87B | |
| +54.11% | 57.64B | |
| +33.59% | 53.37B | |
| +6.02% | 37.83B | |
| +15.88% | 34.11B | |
| -8.32% | 23.18B |
- Stock Market
- Equities
- MEDS Stock
- Financials TRxADE HEALTH, Inc.
